Biochemical and Biophysical Research Communications
Regular ArticleExpression of Three Isoforms of cGMP-Binding cGMP-Specific Phosphodiesterase (PDE5) in Human Penile Cavernosum
References (30)
- et al.
Biochem. Biophys. Res. Commun.
(1990) Adv. Pharmacol.
(1994)Urol. Clin. North Am.
(1995)- et al.
J. Urol.
(1998) - et al.
J. Biol. Chem.
(1993) - et al.
DNA Cell Biol.
(1997) - et al.
Methods Enzymol.
(1988) - et al.
Gene
(1998) - et al.
J. Biol. Chem.
(1998) - et al.
J. Biol. Chem.
(1999)
Science
J. Clin. Invest.
Am. J. Physiol.
Proc. Soc. Exp. Biol. Med.
Cited by (139)
Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease
2020, Mechanisms of Ageing and DevelopmentCitation Excerpt :Despite VSMC heterogeneity during development, PDE5 is highly expressed in VSMCs from almost every organ and is one of the most abundant cGMP-PDEs present in arterial SMCs together with PDE1A, 1B, and 1C, PDE3A and 3B (Liu et al., 2008). Three PDE5 isoforms have been identified in humans, including PDE5A1, PDE5A2, and PDE5A3 that differ in their respective 5′ terminus mRNAs originating from three alternative first exons in the pre-mRNA (Campolo et al., 2018; Kotera et al., 2000; Lin et al., 2000). The three isoforms, that show differential amino acid lengths, are all expressed in aortic VSMCs (Cesarini et al., 2019), possess similar cGMP catalytic activity and are sensitive to PDE5 specific inhibitors (see below) (Lin et al., 2000).
The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction
2019, Sexual Medicine ReviewsOnce upon a Testis: The Tale of Cyclic Nucleotide Phosphodiesterase in Testicular Cancers
2023, International Journal of Molecular SciencesPhosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
2023, European Respiratory ReviewCyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure
2023, Nature Reviews Cardiology
- 1
To whom correspondence should be addressed. Fax: 415-353-9586. E-mail: [email protected].